Full Press Release Details
REGENERON ANNOUNCES PLANS FOR PHASE IIb STUDY OF IL-1 TRAP AND END OF NOVARTIS PARTICIPATION IN IL-1 TRAP PROGRAM Phase IIb Study in Rheumatoid Arthritis Planned for Second Half of 2004.
REGN
REGENERON ANNOUNCES PLANS FOR PHASE IIb STUDY OF IL-1 TRAP AND END OF NOVARTIS PARTICIPATION IN IL-1 TRAP PROGRAM Phase IIb Study in Rheumatoid Arthritis Planned for Second Half of 2004
Key Takeaway: REGENERON ANNOUNCES PLANS FOR PHASE IIb STUDY OF IL-1 TRAP AND END OF NOVARTIS PARTICIPATION IN IL-1 TRAP PROGRAM Phase IIb Study in Rheumatoid Arthritis Planned for Second Half of 2004
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+35%
120-day peak, hindsight
Typical move
2.6%
average across 15 past catalysts
Lead asset
VEGF Trap-Eye
Phase 1 · Diabetic Macular Edema